Search

Background: To explore the association of ALOX5AP single nucleotide polymorphisms (SNPs) and haplotype with the occurrence of cerebral infarction in the Han population of northern China. Methods: Blood samples were collected from 236 patients of Han ancestry with a history of cerebral infarction and 219 healthy subjects of Han ancestry with no history of cerebral infarction or cardiovascular disease. Applied Biosystems® TaqMan® SNP Genotyping Assays for SNP genotyping were used to determine the genotypes of 7 ALOX5AP SNP alleles (rs4073259, rs4769874, rs9315050, rs9551963, rs10507391, rs9579646, and rs4147064). Results: One SNP allele (A) of rs4073259 was significantly associated with development of cerebral infarction (P = 0.049). In comparison to control groups, haplotype rs9315050&rs9551963 AAAC [OR (95% CI) =1.53 (1.02-2.29)], and genotypes rs4147064 CT [OR (95% CI) =1.872 (1.082-3.241)], and rs9551963 AC [OR (95% CI) = 2.015 (1.165-3.484)] increased the risk of cerebral infarction in patients with hypertension. Genotype rs9579646 GG [OR (95% CI) = 2.926 (1.18-7.251)] increased the risk of, while rs4073259 GG [OR (95% CI) = 0.381 (0.157-0.922)] decreased the risk of cerebral infarction in patients with diabetes. Conclusion: These results suggest the ALOX5AP SNP A allele in rs4073259 and genotype rs9579646 GG, rs9551963 AC, and haplotype rs9315050 & rs9551963 AAAC were associated with an increased risk of ischemic stroke in the Han population, while rs4073259 GG was associated with a decreased risk. [ABSTRACT FROM AUTHOR]

Purpose: This study investigates the therapeutic efficacy of various targeted drugs in combination with chemotherapy on advanced/ metastatic triple-negative breast cancer (TNBC) by a network meta-analysis. Methods: Literatures from PubMed, Web of Science, Embase, and CNKI databases were searched to retrieve the relevant published data, and many randomized controlled trials (RCTs) on TNBC were selected according to the inclusion and exclusion criteria. The progression-free survival (PFS), overall survival (OS), the adverse effect rate (AEs), and treatment response rate (RR) of TNBC patients for all retrieved literatures were extracted. R software and Hasse diagrams was used to analyze the therapeutic effects of different targeted drugs combined with chemotherapy. Results: A total of 16 RCTs were included in the study. The PFS (Hazard ratio (HR) 0.72, 95% CI 0.66-0.79, p < 0.001) and OS (HR 0.92, 95% CI 0.84-1.0, p = 0.0475) were calculated among the studies. By comparing with combined regimens, we found that Iniparib combined with chemotherapy has a better therapeutic effect on prolonging PFS (HR p-Score = 0.55, AEs p-Score = 0.80, RR p-Score = 0.82). Conclusion: Based on the network meta-analysis of combined regimens for TNBC patients with PFS, OS, AEs and RR for screening the optimal treatment regimen, we propose that the PFS of patients with TNBC could be improved by a combination chemotherapy including iniparib, cetuximab, taxane or ipatasertib. [ABSTRACT FROM AUTHOR]